Abstract

Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction

Author(s): Andrew Myatt and Ian Eardley

In the aging male, erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) are common conditions that have been shown to be related. As life expectancy increases, treatments that target both ED and LUTS will prove increasingly valuable over the coming years. Phosphodiesterase type 5 (PDE5) inhibitors are used primarily to treat ED. Recently, studies have shown that improvements in LUTS are also seen with PDE5 inhibitor treatment. In particular, the PDE5 inhibitor tadalafil may be beneficial owing to its unique long-acting pharmacokinetic properties. We review the current literature to provide an insight into how tadalafil could provide symptomatic relief from ED and LUTS.